Welcome to the Clinical Trials Office
As you consider treatment options for yourself or your loved one, you may consider participation in a clinical trial. The resources below provide general and specific information that can help you navigate the clinical trial process.
Next Steps for Patients
Complete our patient referral form to learn more about our clinical trials program.
Next Steps for Providers
Complete our patient referral form to connect a patient with our oncology clinical trials program.
Current Clinical Trials
Below is a list of enrolling clinical trials at MaineHealth. Studies can open and close quickly so please contact the Clinical Trials Office directly or speak with your healthcare professional if you are interested in learning more about one of the trials. You can reach the Clinical Trials Office at 207-396-8670 or email at clinicalresearch@mainehealth.org.
For a complete list of trials open in the U.S. and abroad, visit www.clinicaltrials.gov.
(POTS) Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain Learn more
(Regional BKA) A Prospective, Randomized Trial of Liposomal Bupivacaine Compared to Continuous Nerve Catheters on Pain Control and Post-Operative Opioid Use in Receiving Popliteal Nerve Blocks for Below the Knee Amputation Learn more
(ALE1001) A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia Learn more
(ATHN 8: PUPs Matter Study) US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia Learn more
(A011801/ COMPASSHER2) The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib Learn more
(CCTG MA.39) TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer Learn more
(NOHA in BRCA) A Pilot Study of NOHA levels in BRCA positive Breast Cancer
(NOHA in TNBC) A Pilot Study of NOHA as a monitoring biomarker in triple negative breast cancer (TNBC)
(S2212 – SCARLET) Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study Learn more
(WF-2202 – SHINE) Optimizing Psychosocial Intervention for Breast Cancer-Related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial Learn more
(cHOD17) Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 Learn more
(COG AALL1621) A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) Learn more
(COG AALL1732) A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-Lly Learn more
(COG ACCL2031) A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors Learn more
(COG ACCL21C2) Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults With Cancer Learn more
(COG ACNS1821) A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Learn more
(COG ACNS1831) A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) Learn More
(COG ACNS1833) A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Learn more
(COG ACNS1931) A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Learn more
(COG ACNS2021) A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor Learn more
(COG AGCT1531) A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors Learn more
(COG ALTE11C2) Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy Learn more
(COG ANBL2131) A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma Learn more
(COG ANHL1931) A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Learn more
(COG AOST2031) Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma Learn more
(COG APAL2020SC) Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias Learn more
(COG APEC14B1) Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Learn more
(COG AREN03B2) Renal Tumors Classification, Biology, and Banking Study Learn more
(COG AREN1921) Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) Learn more
(COG ARST2032) A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma Learn more
(DFCI 20-302 [Leukemia Profiling]) Protocol for genomically profiling, collecting, archiving and distributing blood and bone marrow specimens from children and young adults with hematologic malignancy. Learn more
(TPX-0005) A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, And Anti-Tumor Activity Study Of Repotrectinib In Pediatric And Young Adult Subjects With Advanced Or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations Learn more
(TransIT) A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) Learn more
(NRG-CC005/ FORTE) Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps Learn more
(NRG-GI008/ CIRCULATE) Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) Learn more
(EA2183) Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body Learn more
(NRG-GU010/ GUIDANCE) Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) Learn more
(NRG-GU013/ High Five) The Phase III ‘High Five Trial’ Five Fraction Radiation for High-Risk Prostate Cancer Learn more
(S1802) Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer Learn more
(EndoMAP/ AFT-50) A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer Learn more
(AOA-PRT-0001) Collection and Banking of Blood Samples for the Study of Female Gynecological Diseases
(EAY191/ ComboMATCH) Molecular Analysis for Combination Therapy Choice (ComboMATCH) Learn more
(GOG-3043/ ROCC) A Phase III Randomized Controlled Trial of Robotic Versus Open Radical Hysterectomy for Cervical Cancer (ROCC) Learn more
(GOG-3078/ GLORIOSA) Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRa-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab Learn more
(NRG-CC008/ SOROCk) A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers Learn more
(NRG-GY019) A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Learn more
(NRG- GY026) A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Learn more
(NRG-GY028) Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers Learn more
(A051901) Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma Learn more
(NeuroOnc mGTB) Study to Assess the Value of Multidisciplinary Genomic Tumor Boards (mGTB) and the Feasibility of Adding a Methylation Array at the Time of Molecular Tumor Testing for Brain Tumors
(NRG-BN003) Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Learn more
(10323/ Moonshot BioBank) Cancer Moonshot Biobank Learn more
(Cardio-Surveillance) Cardio-surveillance of MHCCN Cancer Patients Undergoing Immune Checkpoint Blockade
(DCP-001) Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
(EA8184/ Green Tea Study) A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers Learn more
(EA8192) A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy Learn more
(EA8212/ BRIDGE) A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) Learn more
(FIERCE-HN) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) Learn more
(NRG-BN013) Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases Learn more
(NRG-HN005) A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer Learn more
(KRAS G12C) A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (KRYSTAL-1) Learn more
(NRG-GU009/PREDICT-RT) Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) Learn more
(NRG-HN009) Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Learn more
(SIMPRO) SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice Learn more
(TAPUR) TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) Learn more
(WF-1805CD/ HN-STAR) Implementation and Effectiveness Trial of HN-STAR (HN-STAR) Learn more
(WF-1901/ IMPACTS) Internet-delivered Management of Pain Among Cancer Treatment Survivors Learn more
(WF-2303CD) Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practices (HRSN) Learn more
(A081801/ Alchemist Chemo-IO) Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study Learn more
(A082002) A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer Learn more
(A151216/Alchemist Screening) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Learn more
(LUNGMAP) A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) Learn more
(NRG-LU007/ RAPTOR) RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial Learn more
(CRYPTICS) Randomized Controlled Trial Comparing Dimethyl Sulfoxide Cryopreserved Platelets to Liquid Stored Platelets in Patients Undergoing Cardiopulmonary Bypass Surgery Learn more
(PACES) Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG Learn more
(PRIMARY) Percutaneous or Surgical Mitral Valve Repair Learn more
(TRICS IV) Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery An international, multi-centre, randomized controlled trial to assess transfusion thresholds in younger patients undergoing cardiac surgery Learn more
(ACS FcGammaRlla) Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRlla Learn more
(AMIHOT) A Multi-Center Randomized Post-Approval Evaluation Of The Delivery Of Intracoronary Hyperoxemic Supersaturated Oxygen Therapy For 60 Minutes In Anterior Acute Myocardial Infarction Patients With Successful Reperfusion (VIA PCI) = Six Hours After Symptom O Learn more
(Artemis) Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction Learn more
(ATRIUM) AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis Learn more
(EMPRO) Embolic Protection in Patients Undergoing High-Risk Valve Surgery Learn more
(Maternal Hyperoxia) Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association with Neonatal Neurobehavior
(OCCLUFLEX) Prospective randomized multi-center controlled clinical investigation comparing PFO outcomes of the Occlutech Flex II PFO Occluder to standard of care PFO occlusion Learn more
(PACCS) Pulmonary Artery Catheter in Cardiogenic Shock Trial Learn more
(Philips Ultrasound) Philips Ultrasound Study Protocol – Maine Medical Center
(REACT-AF) Rhythm Evaluation for Anticoagulation with Continuous Monitoring of Atrial Fibrillation Learn more
(REAL AF Registry) Real-world Experience of Catheter Ablation for the Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation Using Novel Contact Force Technologies: REAL AF Registry Learn more
(Short-Cut) Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease-A Randomized Controlled Trial
(Energize) RECOVER-Energize: A Platform Protocol for Evaluation of Interventions for Exercise Intolerance in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Learn more
(RECOVER) NIH RECOVER: A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults Learn more
(BOOST3) Brain Oxygen Optimization in Severe Traumatic Brain Injury—Phase 3 Learn more
(ICECAP) Influence of Cooling duration on Efficacy in Cardiac Arrest Patients Learn more
(PCAS) Inter-individual variables associated with neurological outcomes in Post Cardiac Arrest Syndrome Learn more
(PRECICECAP) A multicenter, observational substudy to the ICECAP trial to define patterns of post-arrest injury (phenotypes) that predict optimal duration of induced hypothermia after cardiac arrest Learn more
(REASSESS ICH) Repeated Assessment of Survivors in Intracerebral Hemorrhage Study Learn more
(Elevating Remote CF Care [Nudge]) Elevating Remote Cystic Fibrosis Care (Nudge App)
(STOP360) Standardizing Treatments for Pulmonary Exacerbations: A platform for evaluating treatment decisions to improve outcomes (STOP360)
N/A
(BADCATS) Beta-adrenergic activation, cardiac dysfunction, and neuroinflammation after aneurysmal subarachnoid hemorrhage Learn more
(ED-ENVISION) ED-INitiated standard Versus HIgh doSe BuprenorphIne InductioON
N/A
(Enhance [HELP]) Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders Learn more
(ATHN 10) Leveraging the ATHNdataset to Document the State of Rare Coagulation Disorders in the United States
(ATHN – Transcends) A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders Learn more
(Community Counts) CDC Public Health Surveillance for Bleeding Disorders – Registry for Bleeding Disorders Surveillance
(Immulina) Effect of Immulina Supplements on Inflammatory Biomarkers Correlated with Clinical Symptoms in Patients with Long COVID (PASC) Learn more
N/A
(iLine) Use of microINR system on elevated INR patients
(TEMPO-4) 58-Week Open Label Trial of TAVAPADON In PARKINSON’S Disease (TEMPo-4 TRIAL) Learn more
(X-TOLE2) Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures Learn more
(ATTACC-CAP) AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia Learn More
(HOTLaser) Comparison of Lumenis Pulse 120H Moses 2.0 holmium laser versus Olympus Soltive thulium fiber laser for mini-percutaneous nephrolithotomy Learn more
(INDV-6000-406) A Phase IV Longitudinal Study of SUBLOCADE (SUBUTEX Prolonged Release) Clinical Outcomes in Adults with Opioid Use Disorder (Opioid Dependence) Learn More
(INDV-6000-407) A Phase IV Study to Evaluate the SUBLOCADE Treatment Exit Strategy Learn More
(PE-TRACT) Pulmonary Embolism – Thrombus Removal With Catheter-Directed Therapy Learn more
(MR-301) A Phase 2, multicenter, double-blind, randomized, placebo-controlled, study to assess the safety of amantadine hydrochloride (HCl) intravenous (IV) solution (MR-301), 50 mg/mL, in patients with severe traumatic brain injury (TBI) Learn more
(ACCQUIREnet) Allied Cleft & Craniofacial Quality-Improvement and Research Network (ACCQUIREnet): Prospective Data-collection System and Learning Health-care Network for the Comprehensive Appraisal of Cleft and Craniofacial Care Learn more
(AWARE) Efficacy of Pharmacologic Management of ADHD in Children and Youth with Autism Spectrum Disorder
(Ensemble-302) An Open-Label, Phase 3 Long-Term Extension (LTE) Study To Assess The Safety, Tolerability, And Efficacy Of Treatment With Pegtibatinase In Participants With Classical Homocystinuria (Hcu) Due To Cystathionine Beta Synthase Deficiency (Ensemble) Learn more
N/A
N/A
N/A
(ADVANCE) EndurAnt Stent Graft system vs ExcluDer endoprothesis: a global, prospectiVe, rANdomized Clinical trial in sac rEgression (ADVANCE) Learn more
(IMPROVE-AD) Improving Outcomes in Vascular Disease-Aortic Dissection Learn more
N/A
GUIDANCE & RESOURCES
If you are thinking about joining a clinical trial, talk to your doctor first. Get as much information as you can about the clinical research and available clinical trials. Because the treatment is new, researchers may not know fully the safety and effectiveness of a new drug, device or medical therapy.
Experimental treatments may not work as well as standard treatments you would have had if you were not participating in a clinical trial. Clinical trial participants may also experience side effects. In many instances, the side effects are no greater in a clinical trial than they would be in standard therapy.
Talk to your doctor to find out if you qualify for cutting-edge care
In a clinical trial, you will get to try new cancer treatments that are specifically focused on your cancer tumor type. Researchers will learn how well the experimental treatment works and patients get extra care and support. For some patients, access to new cancer-fighting drugs and therapies offer hope when standard treatments have not worked. With clinical trials, patients receive:
- Extra support and attention as they undergo new treatments
- The chance to be helped by a brand-new treatment that otherwise is not offered
- The opportunity to help doctors and scientists learn more about treating cancer
- Why participate in a clinical research study? (PDF)
The MaineHealth Cancer Care Network was awarded a grant by the National Cancer Institute (NCI), as a member of the NCI Community Oncology Research Program (NCORP), to implement a new cancer research program that aims to reach more Mainers in their own cities and towns, ensuring they have access to the best possible patient care, including access to more advanced clinical trials in their home communities. If you are a patient and thinking about joining a clinical trial, talk to your doctor first. There is also a form above to self refer. If you are a provider and would like more information about NCORP, please contact the Clinical Trials Office (contact information below).